Table 2 Drugs in clinical development against pathways identified in genomic/proteomic studies

Pan-ErbB receptors

CI-1033

Pfizer

phase II[57, 58]

BIBW-2992

Boehringer Ingelheim

phase II[57, 59]

Neratinib

Wyeth-Ayerst

phase III[60, 61]

MET

MK-2461

Merck

phase I/II[62]

XL184

Exelixis

phase II/III[62]

MetMAb

Genentech

phase I[63]

FGFR

MK-2461

Merck

phase I/II[62]

Brivanib

BMS

phase II[64]

K-RAS-RAF

PLX4032

Plexxikon Inc/Roche

phase I[65]

PI3K-AKT Inhibitors-mTOR

Dual PI3K-mTOR

BEZ235

Novartis

phase I/II[30, 66, 67]

XL765

Exelixis

phase I[68]

SF1126

Semafore

phase I/II[68, 69]

BGT226

Novartis

phase II[68]

PI3K Inhibitors

XL147

Exelixis

phase I[68]

BKM120

Novartis

phase I[68]

GDC0941

Genentech

phase I[70, 71]

AKT inhibitors

Perifosine

Keryx

phsae I/II[72–74]

GSK690693

GSK

phase I[75–77]

MK2206

Merck

phase I[68]

mTOR

OSI027

OSI Pharmaceuticals

phase I[68]

AZD8055

AstraZeneca

phase I/II[68]

MAPK inhibitors

MEK Inhibitors

CI-1040

Pfizer

phase I/II[78, 79]

AZD6244

AstraZeneca

phase I/II[80, 81]

XL518

Genentech

phase I[71]

Cell Cycle

Flavopiridol

Sanofi-aventis

phase II/III[82]

SNS-032

BMS

phase I/II[31]

R-547

Roche

Phase I/II[83, 84]

Seleciclib

Cyclacel Pharmaceuticals

Phase I/II[85]

Histone Deacetylase inhibitors

Vorinostat (SAHA)

Merck

Phase I/II[86]

Romidepsin

Gloucester Pharmaceuticals

Phase I/II[87, 88]

MGCD0103

MethylGene, Inc

phase I/II[89]

LBH589

Novartis

phase I/II[90, 91]

Demethylating agents

Azacitidine

Celgene

approved[92, 93]

Decitabine

Eisai Pharmaceuticals

approved[94]

DNA repair

PARP

Olaparib

KuDOS Pharmaceuticals/AstraZeneca

phase II[95]

AG-014699

Pfizer

phase II[96]

ATM

KU-55933

KuDOS Pharmaceuticals

preclinical[97]

Matrix Metalloproteinases

Neovastat

Æterna Laboratories

phase III[98, 99]

Prinomastat

Pfizer

phase III[98, 100, 101]